Potent ex vivo expanded, human CD34+ cord blood-derived natural killer cells for cancer immunotherapy.

Background Clinical studies suggest that adoptive transfer of allogeneic natural killer (NK) cells represent a promising treatment for patients with hematological malignancies and solid tumors. Celgene Cellular Therapeutics has established a cultivation process to generate human NK cells from umbilical cord blood (UCB) CD34 cells with substantial cytolytic activity against several human tumor cell lines.